ArticleJournal of virology2024
The replication-competent HIV reservoir is a genetically restricted, younger subset of the overall pool of HIV proviruses persisting during therapy, which is highly genetically stable over time.
Abstract read
In one paragraph
Article in Journal of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- The rebound-initiating viral reservoir (RIVR) in SIV/SHIV infection is dominated by plasma virus sequences present at the time of ART initiation.Journal of virology · 2026Article
- Variations and evolution of HIV-1 provirus in peripheral blood under the pressure of ART.Virus evolution · 2026Article
- Ultra-low level HIV p24 drives immune activation in antiretroviral therapy-treated people living with HIV.Communications medicine · 2025Article
- Rapid clearance of inducible HIV-1 proviruses after initiation of antiretroviral therapy.PLoS pathogens · 2025Article
- Selective decline of intact HIV reservoirs during the first decade of ART followed by stabilization in memory T cell subsets.AIDS (London, England) · 2025Article
- EZH2 inhibition mitigates HIV immune evasion, reduces reservoir formation, and promotes skewing of CD8Cell reports · 2025Article
- SIV proviruses seeded later in infection are harbored in short-lived CD4Cell reports · 2025Article
- Barcoded HIV-1 reveals viral persistence driven by clonal proliferation and distinct epigenetic patterns.Nature communications · 2025Article
- HIV-1 Rebound Virus Consists of a Small Number of Lineages That Entered the Reservoir Close to ART Initiation.bioRxiv : the preprint server for biology · 2025Article
- A simple phylogenetic approach to analyze hypermutated HIV proviruses reveals insights into their dynamics and persistence during antiretroviral therapy.Virus evolution · 2025Article
- A simple phylogenetic approach to analyze hypermutated HIV proviruses reveals insights into their dynamics and persistence during antiretroviral therapy.Research square · 2024Article
- Quantitative and Qualitative Distinctions between HIV-1 and SIV Reservoirs: Implications for HIV-1 Cure-Related Studies.Viruses · 2024Review
- HIV Expression in Infected T Cell Clones.Viruses · 2024Review
Corrections and comments
- Update of
Authors and funding
23 authors.
Aniqa ShahidFaculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Signe MacLennanFaculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Bradley R JonesBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Hanwei SudderuddinBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Zhong DangBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Kyle CobarrubiasBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Maggie C DuncanFaculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Natalie N KinlochFaculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Michael J DappDepartment of Microbiology, University of Washington, School of Medicine, Seattle, Washington, USA.
Nancie M ArchinUNC HIV Cure Center, Institute of Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0002-7938-0389
Margaret A FischlDepartment of Medicine, University of Miami School of Medicine, Miami, Florida, USA.
Igho OfotokunDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Adaora AdimoraDepartment of Epidemiology, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Stephen GangeDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Bradley AouizeratCollege of Dentistry, New York University, New York, New York, USA.
Mark H KuniholmDepartment of Epidemiology and Biostatistics, University at Albany, State University of New York, Rensselaer, New York, New York, USA.
Seble KassayeDivision of Infectious Diseases and Tropical Medicine, Georgetown University, Washington, DC, USA.
James I MullinsDepartment of Microbiology, University of Washington, School of Medicine, Seattle, Washington, USA.
Harris GoldsteinDepartments of Microbiology and Immunology and Pediatrics, Albert Einstein College of Medicine, Bronx, New York, New York, USA.
Jeffrey B JoyBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Kathryn AnastosDepartment of Medicine, Albert Einstein College of Medicine, New York, New York, USA.
Zabrina L BrummeFaculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.ORCID 0000-0002-8157-1037
MACS/WIHS combined cohort study (MWCSS)
Funding
UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1MVirology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Latesha Ellen Elopre · 1988 to 2026
$84.1MEngaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0MVirology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9MVirology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0MQAQC Johns Hopkins Institute for Clinical and Translational ResearchUL1TR003098 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2019 to 2023
$57.7MMaternal Morbidity and Mortality: Risk Factors, Early Detection and Personalized InterventionUL1TR001409 · NCATS · GEORGETOWN UNIVERSITY · PI GONDRE-LEWIS, MARJORIE C, MELLMAN, THOMAS A · 2015 to 2024
$37.8MSF Bay Area MACS/WIHS Combined Cohort StudyU01HL146242 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bradley E Aouizerat, Jennifer Cohen Price · 2019 to 2026
$36.3MSex differences in the role of multi-omicsin HIV-associated carotid artery atherosclerosisU01HL146193 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Stephen J Gange, Elizabeth Topper · 2019 to 2026
$35.8MUniversity of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GWENDOLYN Barbara SCOTT · 2007 to 2026
$33.8MClinical Research Sites for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS) - Baltimore/Wash DC Center - Admin Supplement: Vision and dual sensory loss in HIV-infected older adultsU01HL146201 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI TODD T BROWN, Joseph B. Margolick · 2019 to 2026
$33.7MSex differences in the role of multi-omics in HIV-associated carotid artery atherosclerosisU01HL146204 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI David B. Hanna, Anjali Sharma · 2019 to 2026
$33.2MCIHRNCATS NIH HHS KL2 TR001432NCATS NIH HHS TL1 TR001431NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1 TR001409NCATS NIH HHS UL1 TR001881NCATS NIH HHS UL1 TR003098NHLBI NIH HHS U01 HL146192NHLBI NIH HHS U01 HL146193NHLBI NIH HHS U01 HL146194NHLBI NIH HHS U01 HL146201NHLBI NIH HHS U01 HL146202NHLBI NIH HHS U01 HL146203NHLBI NIH HHS U01 HL146204NHLBI NIH HHS U01 HL146205NHLBI NIH HHS U01 HL146208NHLBI NIH HHS U01 HL146240NHLBI NIH HHS U01 HL146241NHLBI NIH HHS U01 HL146242NHLBI NIH HHS U01 HL146245NHLBI NIH HHS U01 HL146333NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI073961NIAID NIH HHS P30 AI124414NIAID NIH HHS UM1 AI164565NIMH NIH HHS P30 MH116867
Abstract
Within-host HIV populations continually diversify during untreated infection, and this diversity persists within infected cell reservoirs during antiretroviral therapy (ART). Achieving a better understanding of on-ART proviral evolutionary dynamics, and a better appreciation of how the overall persisting pool of (largely genetically defective) proviruses differs from the much smaller replication-competent HIV reservoir, is critical to HIV cure efforts. We reconstructed within-host HIV evolutionary histories in blood from seven participants of the Women's Interagency HIV Study who experienced HIV seroconversion, and used these data to characterize the diversity, lineage origins, and ages of proviral
Indexed as
HIV-1HIV InfectionsProvirusesCD4-Positive T-LymphocytesChildFemaleHumansViral LoadVirus Integrationgenetic stabilityHIVmolecular datingpersistencephylogeneticsrebound
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.